Clinical trials: Plasma Cell Tumor
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
The purpose of this study is to compare the effects (good and bad) of the medication basiliximab in combination with cyclosporine (investigational therapy) for the prevention of a complication of bone marrow transplantation known…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT00975975
- Testing
- Basiliximab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Indiana University
Quality of Life, Multiple Myeloma
Quality of Life the Danish Multiple Myeloma Patients
The aim of the project is to improve quality of life for multiple myeloma patients in the future.
- Trial name
- QoL-MM (NCT02892383)
- Where
- 10 sites in Denmark
- Volunteers
- 681 people
- Sponsor
- Odense University Hospital
Hodgkin Lymphoma, Non Hodgkin Lymphoma
Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events
The purpose of this study is to monitor physiological and molecular changes during and following CAR-T cancer cell therapy, towards improved management of adverse events including Cytokine Release Syndrome and neurotoxicity.
- Conditions
- Hodgkin Lymphoma, Non Hodgkin Lymphoma, Leukemia, Multiple Myeloma
- Trial name
- NCT05123001
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
Multiple Myeloma
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the efficacy of teclistamab daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd) or daratumumab SC in combination with…
- Trial name
- MajesTEC-3 (NCT05083169)
- Testing
- Daratumumab, Pomalidomide, Dexamethasone
- Where
- 176 sites in United States, Argentina and 19 more
- Volunteers
- 587 people
- Sponsor
- Janssen Research & Development, LLC
Myeloproliferative Disorders, Lymphoproliferative Disorders
In Vitro Drug Sensitivity Testing of Fresh Human Samples
Hematological malignancies gather several various pathologies included myeloproliferative disorders (as acute myeloid leukemia (AML) or chronic myeloid leukemia (CML)) and lymphoproliferative disorders (as chronic lymphoid…
- Trial name
- ESAAC (NCT05001386)
- Testing
- Blood collection for the evaluation of the anti-drugs sensitivity
- Where
- 2 sites in France
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Multiple Myeloma, Relapse Multiple Myeloma
B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma
For the treatment of relapsed and refractory MM, the Chinese Guidelines for the Diagnosis and Treatment of Multiple Myeloma pointed out that relapsed MM is highly heterogeneous, and individualized evaluation of relapsed patients…
- Conditions
- Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT05150522
- Testing
- BCMA CAR-T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen University General Hospital
Multiple Myeloma (MM)
Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma
This is a prospective, single-arm, single-center interventional study designed to evaluate the safety and efficacy of Elra-Isa-VR in patients with newly diagnosed ultra-high-risk multiple myeloma.
- Trial name
- HRMM-001 (NCT07789522)
- Testing
- anti-BCMA/CD3 bispecific antibody
- Volunteers
- 15 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT
The purpose of this study is to evaluate the efficacy and safety of salvage treatment with carfilzomib/lenalidomide/dexamethasone (KRD) followed by 2nd autologous stem cell transplantation (ASCT) and lenalidomide maintenance in…
- Trial name
- KMM1911 (NCT05497102)
- Testing
- Lenalidomide maintenance
- Where
- South Korea
- Volunteers
- 58 people
- Sponsor
- Samsung Medical Center
Multiple Myeloma and Plasma Cell Neoplasm
Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003603
- Testing
- cyclophosphamide, dexamethasone, idarubicin
- Where
- United Kingdom
- Volunteers
- 660 people
- Sponsor
- Riverside Haematology Group
Lymphoma, Non-Hodgkin, Multiple Myeloma
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
The purpose of this study is to evaluate of the study of different CNTO 328 doses and schedules and to see if CNTO 328 has any effect on Non-hodgkin's Lymphoma, Multiple Myeloma or Castleman's disease.
- Conditions
- Lymphoma, Non-Hodgkin, Multiple Myeloma, Giant Lymph Node Hyperplasia
- Trial name
- NCT00412321
- Testing
- CNTO 328
- Where
- 9 sites in United States
- Volunteers
- 67 people
- Sponsor
- Centocor, Inc.
Multiple Myeloma(MM)
Serum NGAL IN Patients With Multiple Myeloma
The aim of this study was to evaluate SERUM neutrophil gelatinase-associated lipocalin, emerging indicator of tubular damage and examine their relationship with established measures of renal function (serum creatinine, and…
- Trial name
- NCT05439538
- Testing
- SERUM NGAL
- Volunteers
- 60 people
- Sponsor
- Assiut University
Multiple Myeloma
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of cilta-cel out-of-specification (OOS).
- Trial name
- NCT05347485
- Testing
- Cilta-cel, Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)
- Where
- 18 sites in United States
- Volunteers
- 86 people
- Sponsor
- Janssen Scientific Affairs, LLC
Carcinoma, Sarcoma
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative
This study is the first time that a new experimental drug called [18F]-SKI-249380 is being used in people. [18F]-SKI-249380 is not a therapeutic drug.
- Conditions
- Carcinoma, Sarcoma, Myeloma, Lymphoma
- Trial name
- NCT01916135
- Testing
- [18F]-SKI-249380, PET/CT scan, Blood draws
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)
Study Phase: phase 1 and phase 2 Objective: Evaluation of the effect of lenalidomide, cyclophophamide and prednisone (REP) in patients with relapsed multiple myeloma previously treated with lenalidomide Study design: prospective…
- Trial name
- REPEAT (NCT01352338)
- Testing
- Lenalidomide, endoxan, prednisone
- Where
- 3 sites in Netherlands
- Volunteers
- 82 people
- Sponsor
- UMC Utrecht
Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Sleep Apnea in Patients With MGUS and MM
This study involves patients with plasma cell dyscrasia including monoclonal gammopathy of undetermined significance (MGUS) or multiple myeloma (MM), with and without sleep apnea, who are providing bone marrow specimens.
- Trial name
- NCT04114084
- Testing
- Bone Marrow Aspirate and Biopsy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Michael Tomasson
Multiple Myeloma
Institut Paoli Calmettes Multiple Myeloma Database
Database of Institut Paoli-Calmettes patients diagnosed with multiple myeloma
- Trial name
- NCT02869555
- Testing
- Data collection
- Where
- France
- Volunteers
- 5,000 people
- Sponsor
- Institut Paoli-Calmettes
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00054158
- Testing
- dexamethasone, doxorubicin hydrochloride, thalidomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Roswell Park Cancer Institute
Multiple Myeloma
Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma
The primary objective is overall survival (OS) as predicted by baseline self-reported EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30) fatigue scale ratings…
- Trial name
- CLARITY (NCT03190525)
- Testing
- Quality of life questionnaires
- Where
- 35 sites in Italy, United Kingdom
- Volunteers
- 530 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Multiple Myeloma
Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma
To provide elotuzumab treatment for single-patient use.
- Trial name
- NCT02541643
- Testing
- Elotuzumab
- Where
- United States
- Sponsor
- Sundar Jagannath
Multiple Myeloma
Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old
This protocol is a national, multicenter, comparative, open-label, randomized trial comparing the progression free survival (PFS) of two pre-transplant conditioning regimens (BUMEL versus. MEL-200).
- Trial name
- GEM2012MENOS65 (NCT01916252)
- Testing
- bortezomib (Velcade ®), lenalidomide (Revlimid®), busulfan (Busilvex ®)
- Where
- 74 sites in Spain
- Volunteers
- 460 people
- Sponsor
- PETHEMA Foundation